DE Shaw Research has backed a series A round for Relay Therapeutics, launched yesterday to commercialise research from Shaw and a range of universities.
US-based biotechnology developer Relay Therapeutics launched yesterday with $57m in series A funding from biochemistry research company DE Shaw Research and venture capital firm Third Rock Ventures.
Relay Therapeutics is working on a drug discovery platform based on protein motion. The approach exploits a new understanding of dynamic structural changes undergone by protein molecules in the human body.
Relay is initially focusing on cancer treatments but hopes its technology can be applied to a range of diseases for which no…
